Xiaoping Wang
Department of Breast Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Breast Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2002 | Institute of Biophysics, the Chinese Academy of Sciences, Sichuan University, Beijing, CHN, PHD, Science |
Experience & Service
Academic Appointments
Senior Research Scientist, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - 2018
Research Scientist, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - 2016
Postdoctoral Fellow, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2002 - 2008
Institutional Committee Activities
Member, The Morgan Welch Inflammatory Breast Cancer Research Program Multidisciplinary Grant Planning Committee, 2021 - 2021
Committee Member, Morgan Welch Inflammatory Breast Cancer Research Program and Clinic Research Fundamentals Education Committee, 2021 - 2021
Reviewer, The Zeta Tau Alpha Houston Alumnae Association Fellowship in Inflammatory Breast Cancer Research Review Committee, 2019 - 2019
Committee Member, Inflammatory Breast Cancer International Symposium Committee, 2019 - Present
Committee Member, Morgan Welch Inflammatory Breast Cancer Research Program and Clinic Rare Tumor Initiative Planning Committee, 2019 - Present
Honors & Awards
| 2018 | The Zeta Tau Alpha Houston Alumnae Association Fellowship in Inflammatory Breast Cancer Research |
| 2012 | The Ninth Annual Division of Cancer Medicine Employee Citation for Excellence in Laboratory Research Award, The University of Texas MD Anderson Cancer Center |
| 1997 | Scholarship, Chinese Academy of Sciences Yi-Li-Da |
| 1995 | Scholarship, Sichuan University |
Selected Publications
Peer-Reviewed Articles
- Masuda H, Harano K, Miura S, Wang Y, Hirota Y, Harada O, Jolly MK, Matsunaga Y, Lim B, Wood AL, Parinyanitikul N, Jin Lee H, Gong G, George JT, Levine H, Lee J, Wang X, Lucci A, Rao A, Schweitzer BL, Lawrence OR, Seitz RS, Morris SW, Hout DR, Nakamura S, Krishnamurthy S, Ueno NT. Changes in triple-negative breast cancer molecular subtypes in patients without pathologic complete response after neoadjuvant systemic chemotherapy. JCO Precis Oncol 6:e2000368, 2022. PMID: 35294223.
- Semba T, Wang X, Xie X, Cohen EN, Reuben JM, Dalby KN, Long JP, Phi LTH, Tripathy D, Ueno NT. Identification of JNK active triple-negative breast cancer cluster associated with immunosuppressive tumor microenvironment. J Natl Cancer Inst 114(1):97-108, 2022. e-Pub 2021. PMID: 34250544.
- Park J, Tacam MJ, Chauhan G, Cohen EN, Gagliardi M, Iles LR, Ueno NT, Battula VL, Sohn YK, Wang X, Kim HS, Krishnamurthy S, Fowlkes NW, Green MM, Bartholomeusz GA, Tripathy D, Reuben JM, Bartholomeusz C. Nonphosphorylatable PEA15 mutant inhibits epithelial‑mesenchymal transition in triple‑negative breast cancer partly through the regulation of IL‑8 expression. Breast Cancer Res Treat 189(2):333-45, 2021. e-Pub 2021. PMID: 34241740.
- Iwase T, Wang X, Shrimanker TV, Kolonin MG, Ueno NT. Body composition and breast cancer risk and treatment: mechanisms and impact. Breast Cancer Res Treat 186(2):273-83, 2021. PMID: 33475878.
- Hu X, Villodre ES, Larson R, Rahal OM, Wang X, Gong Y, Song J, Krishnamurthy S, Ueno NT, Tripathy D, Woodward WA, Debeb BG. Decorin-mediated suppression of tumorigenesis, invasion, and metastasis in inflammatory breast cancer. Commun Biol 4(1):72, 2021. PMID: 33452400.
- Wang X, Semba T, Phi LTH, Chainitikun S, Iwase T, Lim B, Ueno NT. Targeting signaling pathways in inflammatory breast cancer. Cancers (Basel) 12(9):2479, 2020. PMID: 32883032.
- Su F, Wang X, Pearson T, Lee J, Krishnamurthy S, Ueo NT, Kolonin MG. Ablation of stromal cells with a targeted proapoptotic peptide suppresses cancer chemotherapy resistance and metastasis. Mol Ther Oncolytics(18):579-586, 2020. PMID: 32995482.
- Semba T, Sammons R, Wang X, Xie X, Dalby KN, and Ueno NT. JNK signaling in stem cell self-renewal and differentiation. Int. J. Mol. Sci 21(7):2613, 2020. PMID: 32283767.
- Bertucci F, Rypens C, Finetti P, Guille A, Adélaïde J, Monneur A, Carbuccia N, Garnier S, Dirix P, Gonçalves A, Vermeulen P, Debeb BG, Wang X, Dirix L, Ueno NT, Viens P, Cristofanilli M, Chaffanet M, Birnbaum D, Van Laere S. NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non‐inflammatory breast cancers. Mol. Oncol 14(3):504-19, 2020. e-Pub 2020. PMID: 31854063.
- Funakoshi Y, Wang Y, Semba T, Masuda H, Hout D, Ueno NT, Wang X. Comparison of molecular profile in triple-negative inflammatory and non-inflammatory breast cancer not of mesenchymal stem-like subtype. PLoS One 14(9):e0222336. e-Pub 2019. PMID: 31532791.
- *Matsuda N, *Wang X, Lim B, Krishnamurthy S, Alvarez RH, Willey JS, Parker CA, Song J, Shen Y, Hu J, Wu W, Li N, Babiera GV, Murray JL, Arun BK, Brewster AM, Reuben JM, Stauder MC, Barnett CM, Woodward WA, Le-Petross HTC, Lucci A, DeSnyder SM, Tripathy D, Valero V, Ueno NT. Safety and efficacy of panitumumab plus neoadjuvant chemotherapy in patients with primary HER2-negative inflammatory breast cancer. JAMA Oncol 4(9):1207-13, 2018. PMID: 29879283.
- Lim B, Woodward WA, Wang X, Reuben JM, Ueno NT. Inflammatory breast cancer biology: the tumor microenvironment is key. Nat Rev Cancer 18(8):485-99, 2018. PMID: 29703913.
- Woodward WA, Cristofanilli M, Merajver SD, Van Laere S, Pusztai L, Bertucci F, Berditchevski F, Polyak K, Overmoyer B, Devi GR, Sterneck E, Schneider R, Debeb BG, Wang X, van Golen KL, El-Zein R, Rahal OM, Alexander A, Reuben IM, Krishnamurthy S, Lucci A, Ueno NT. Scientific Summary from the Morgan Welch Inflammatory Breast Cancer (IBC) Program 10th Anniversary Conference. J Cancer 8(17):3607-14, 2017. PMID: 29667990.
- Wang X, Reyes ME, Zhang D, Funakoshi Y, Trape AP, Gong Y, Kogawa T, Eckhardt BL, Masuda H, Pirman DA, Yang P, Reuben JM, Woodward WA, Bartholomeusz C, Hortobagyi GN, Tripathy D, Ueno NT. EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer. Oncotarget 8(40):67904-17, 2017. e-Pub 2017. PMID: 28978083.
- Reyes ME, Fujii T, Branstetter D, Krishnamurthy S, Masuda H, Wang X, Reuben JM, Woodward WA, Edwards BJ, Hortobagyi GN, Tripathy D, Dougall WC, Eckhardt BL, Ueno NT. Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression. Breast Cancer Res Treat 164(1):57-68, 2017. PMID: 28417335.
- Daquinag A, Dadbin A, Snyder B, Wang X, Sahin A, Ueno NT, Kolonin M. Non-glycanated Decorin is a drug target on human adipose stromal cells. Mo Ther Oncolytics 6:1-9, 2017. e-Pub 2017. PMID: 28607949.
- Matsuda N, Lim B, Wang X, Ueno NT. Early clinical development of epidermal growth factor receptor targeted therapy in breast cancer. Expert Opin Investig Drugs 26(4):463-79, 2017. e-Pub 2017. PMID: 28271910.
- Kai K, Kondo K, Wang X, Xie X, Pitner MK, Reyes ME, Torres-Adorno AM, Masuda H, Hortobagyi GN, Bartholomeusz C, Saya H, Tripathy D, Sen S, Ueno NT. Antitumor activity of KW-2450 against triple-negative breast cancer by inhibiting Aurora A and B kinases. Mol Cancer Ther 14(12):2687-99, 2015. e-Pub 2015. PMID: 26443806.
- Wang X, Ueno NT. NSAID use reduces breast cancer recurrence in overweight and obese women: role of prostaglandine aromatase interactions. Cancer Res 74(16):4446-57, 2014. PMID: 25125682.
- Bhattacharya S, Lou X, Hwang P, Rajashankar KR, Wang X, Gustafsson J, Fletterick RJ, Jacobson RH, Webb P. Structural and functional insight into TAF1-TAF7, a subcomplex of transcription factor II D. Proc Natl Acad Sci U S A 111(25):9103-8, 2014. e-Pub 2014. PMID: 24927529.
- Wang X, Saso H, Iwamoto T, Xia W, Gong Y, Pusztai L, Woodward WA, Reuben JM, Warner SL, Bearss DJ, Hortobagyi GN, Hung MC, Ueno NT. TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase. Cancer Res 73(21):6516-25, 2013. e-Pub 2013. PMID: 24014597.
- Rayala SK, Martin E, Sharina IG, DenHollander P, Wang X, Jacobson RH, Murad F, Kumar R. Dynamic interplay between nitration and phosphorylation of tubulin cofactor B in the control of microtubule dynamics. Proc Natl Acad Sci U S A 104(49):19470-5, 2007. e-Pub 2007. PMID: 18048340.
- Wang X, Truckses DM, Takada S, Tanese N, Matsumura T, Jacobson RH. Conserved region I of human coactivator TAF4 binds to a short hydrophobic motif present in transcriptional regulators. Proc Natl Acad Sci U S A 104(19):7839-44, 2007. e-Pub 2007. PMID: 17483474.
- Wang X, Han X, Yang F. Critical segment of apocytochrome c for its insertion into membrane. Mol Cell Biochem 262(1-2):61-9, 2004. PMID: 15532710.
- Wang X, Han X, Yang F. Peptide 68-88 of apocytochrome c plays a crucial role in its insertion into membrane and binding to mitochondria. Sci China C Life Sci 46(1):18-27, 2003. PMID: 20213358.
- Wang X, Han X, Jia S, Yang F. Change of apocytochrome c translocation across membrane in consequence of hydrophobic segment deletion. Mol Cell Biochem 233(1-2):39-47, 2002. PMID: 12083378.
- Wang X, Miao Q, Han X. Specific targeting of apocytochrome c to mitochondria. Chinese J Biochem Mol Bio 15(5):813-9, 1999.
Abstracts
- Semba T, Xie X, Cohen EN, Reuben JM, Dalby KN, Wang X, and Ueno NT. Suppression of tumorigenicity and metastasis of triple-negative breast cancer (TNBC) by C-JUN N-Terminal Kinase (JNK) inhibitor via reversing immunosuppressive tumor microenvironment (TME). 6th Annual Immuno-Oncology Young Investigators’ Forum, 2020.
- Semba T, Xie X, Cohen EN, Reuben JM, Dalby KN, Wang X, and Ueno NT. Suppression of tumorigenicity and metastasis of triple-negative breast cancer (TNBC) by C-JUN N-Terminal Kinase (JNK) inhibitor via reversing immunosuppressive tumor microenvironment (TME). AACR Virtual Annual Meeting, 2020.
- Wang X, Shao S, Semba T, Pearson T, Reuben JM, Tripathy D, and Ueno NT. Immune modulation with humanized anti-EGFR antibody panitumumab in an immunocompetent mouse model for inflammatory breast cancer. AACR Annual Meeting, 2019.
- Wang X, Shao S, Pearson T, Cheng Y, Reuben JM, Tripathy D, and Ueno NT. Immune modulation with humanized anti-EGFR antibody panitumumab in an immunocompetent mouse model for inflammatory breast cancer. 41th Annual San Antonio Breast Cancer Symposium, 2018.
- Cheng Y, Funakoshi Y, Wang X, Warner SL, Bearss DJ, and Ueno NT. TP-0903 inhibits inflammatory breast cancer progression and M2 macrophage polarization. 41th Annual San Antonio Breast Cancer Symposium, 2018.
- Wang X, Matsuda N, Lim B, Krishnamurthy S, Song J, Shen Y, Wu W, Hu J, Woodward WA, Reuben JM, Lucci A, Tripathy D, Valero V, and Ueno NT. Identification of biomarkers predictive of response to panitumumab combined with neoadjuvant chemotherapy for primary inflammatory breast cancer. AACR Annual Meeting 2018, 2018.
- Wang X, Reyes ME, Zhang D, Funakoshi Y, Trape AP, Gong Y, Kogawa T, Eckhardt BL, Masuda H, Pirman, Jr. DA, Yang P, Reuben JM, Woodward WA, Bartholomeusz C, Hortobagyi GN, Tripathy D, Ueno NT. The EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer. Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference: The Future of Inflammatory Breast Cancer, 2017.
- Funakoshi Y, Wang X, Warner SL, Bearss DJ, Ueno NT. TP-0903 suppresses both proliferation of inflammatory breast cancer and THP-1 derived M2 macrophage polarization. Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference: The Future of Inflammatory Breast Cancer, 2017.
- Willey JS, Parker C, Lim B, Le-Petross H, Krishnamurthy S, Woodward W, Lucci A, Sun H, Wood A, Marx A, Babiera G, Soon J, Shen Y, Valero V, Wang X, Ueno NT. A randomized phase II study of neoadjuvant carboplatin/paclitaxel (CT) versus panitumumab/carboplatin/paclitaxel (PaCT) followed by anthracycline-containing regimen for newly diagnosed primary triple-negative inflammatory breast cancer (2016-0177)-ongoing trial. 40th Annual San Antonio Breast Cancer Symposium, 2015.
- Matsuda N, Alvarez RH, Krishnamurthy S, Wiley JS, Wang X, Lim B, Parker CA, Marx AN, Babiera GV, Booser DJ, Murray JL, Arun BK, Brewster A, Reuben JM, Woodward WA, Lucci A, DeSnyder SM, Tripathy D, Valero V, Ueno NT. Phase II study of panitumumab, Nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER-2 negative inflammatory breast cancer. ASCO Annual Meeting, 2015.
- Wang X, Masuda H, Woodward WA, Reuben JM, Alvarez RH, Valero V, Ueno NT. Src pathway mediates cancer stem cells through Notch signaling in inflammatory breast cancer. 4th International Inflammatory Breast Cancer Conference, 2014.
- Reyes ME, Zhang D, Eckhardt B, Masuda H, Pirman DA, Reuben JM, Woodward WA, Yang P, Hortobagyi GN, Wang X, Ueno NT. Targeting COX-2 to reduce stem-like phenotype of inflammatory breast cancer via Nodal signaling. 37th Annual San Antonio Breast Cancer Symposium, 2013.
- Reyes ME, Masuda H, Zhang D, Reuben JM, Woodward WA, Darnay BG, Hortobagyi GN, Wang X, Ueno NT. Receptor activator of nuclear factor Kappa B (RANK) as a potential therapeutic target in triple-negative breast cancer. 2013 SACNAS National Conference, 2013.
- Wang X, Saso H, Iwamoto T, Xia W, Gong Y, Pusztai L, Woodward WA, Reuben JM, Hortobagyi GN, Hung MC, Ueno NT. Tazarotene-induced gene 1 promotes tumorigenicity and invasiveness of inflammatory breast cancer through receptor tyrosine kinase Axl. AACR Annual Meeting 2013, 2013.
Grant & Contract Support
| Title: | Enhancing EGFR-targeted therapy by blocking immunosuppression in the tumor microenvironment in inflammatory breast cancer |
| Funding Source: | Emerson Collective |
| Role: | Principal Investigator |
| Title: | Enhancing anti-EGFR Therapeutic Efficacy in Inflammatory Breast Cancer |
| Funding Source: | NCI R01 |
| Role: | Co-Investigator |
| Title: | Enhancing the efficacy of Axl inhibitor TP-0903 in inflammatory breast cancer and triple-negative breast cancer |
| Funding Source: | Tolero Pharmaceuticals |
| Role: | Principal Investigator |
| Title: | Development of novel therapy by targeting the tumor microenvironment in inflammatory breast cancer |
| Funding Source: | BCRF |
| Role: | Co-Investigator |
| Title: | Enhancing Axl-targeted therapy in inflammatory breast cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | Principal Investigator |
| Title: | Enhancing Axl-targeted therapy by targeting the tumor microenvironment in inflammatory breast cancer |
| Funding Source: | IRG |
| Role: | Principal Investigator |
| Title: | Enhancing Axl-targeted therapy in inflammatory breast cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | Principal Investigator |
| Title: | Development of novel tumor microenvironment targeted therapy in inflammatory breast cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-Investigator |
| Title: | Development of novel therapy by targeting the tumor microenvironment in inflammatory breast cancer |
| Funding Source: | BCRF |
| Role: | Co-Investigator |
| Title: | Development of novel therapy by targeting the tumor microenvironment in inflammatory breast cancer |
| Funding Source: | BCRF |
| Role: | Co-Investigator |
| Title: | Targeting the tumor microenvironment in inflammatory breast cancer |
| Funding Source: | BCRF |
| Role: | Co-Investigator |
| Title: | Adipose stromal cell targeting: A new approach to breast cancer treatment |
| Funding Source: | NCI-UTHSC Houston R21 |
| Role: | Co-Investigator |
| Title: | Development of novel therapy by targeting the tumor microenvironment in inflammatory breast cancer |
| Funding Source: | BCRF |
| Role: | Co-Investigator |